文献速递免疫规划

mRNA与BBV152疫苗加强针对奥密克戎亚变异株的免疫原性:PRIBIVAC研究B阶段随机临床试验最终结果

Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial.
PubMed 文献 · Vaccine · 2024-09-05

PRIBIVAC研究B阶段将50名已接种mRNA疫苗者随机分配接受mRNA加强针(n=26)或BBV152加强针(n=24)。结果显示,第28天和第180天mRNA组抗刺突抗体滴度及针对奥密克戎亚变异株BA.1/BA.2的替代病毒中和抗体水平显著高于BBV152组,但两组突破感染率与感染时间相似;至第360天两组抗体水平趋于一致。

要点

  • 第28天mRNA组抗刺突抗体滴度显著高于BBV152组。
  • 第180天mRNA组针对BA.1/BA.2的中和抗体仍显著更高。
  • 第360天两组抗体水平及突破感染时间相似。

核心结论

  • 接种mRNA加强针者第28天和第180天的野生型SARS-CoV-2抗刺突抗体滴度及针对野生型及奥密克戎亚变异株BA.1/BA.2/BA.5的替代病毒中和抗体水平显著高于接种BBV152加强针者。

研究设计与样本

  • 随机、受试者盲法、对照试验,50名已接种mRNA疫苗的受试者随机接受mRNA加强针(n=26)或BBV152加强针(n=24)。
  • 于加强前及加强后第7、28、180、360天采集血样分析体液和细胞免疫应答,主要终点为第28天SARS-CoV-2抗刺突抗体滴度。

主要发现

  • 第28天BBV152组平均抗刺突抗体滴度为2004 IU/mL(95%CI 1132-3548),mRNA组为26669 IU/mL(95%CI 21330-33266),p<0.0001,但两组刺突特异性CD4和细胞毒性T细胞水平相当。
  • 第180天BBV152组抗刺突抗体滴度为4467 IU/mL(95%CI 1959-10186),mRNA组为20749 IU/mL(95%CI 12303-35075),p=0.0017。
  • 第180天mRNA组针对祖先株及奥密克戎亚变异株BA.1和BA.2的替代病毒中和抗体水平显著更高,校正期间感染后仍如此。
  • 至第360天两组抗刺突抗体滴度及针对奥密克戎亚变异株的中和抗体水平变得相似。
  • 研究结束时每组各16例发生突破感染(mRNA组64%,BBV152组69.6%),两组COVID-19感染时间相似(p=0.63)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 招募于2022年1月开始,因BBV152组达到预设无效性标准而提前终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: BBV152 (Covaxin™) is a whole-virion inactivated SARS-CoV-2 vaccine mixed with an immune adjuvant. We aimed to compare immune responses after booster vaccination with heterologous BBV152 versus homologous mRNA vaccine. METHODS: We conducted a randomized, participant-blinded, controlled trial. Fifty mRNA-vaccinated participants were enrolled and randomized to receive an mRNA booster (n = 26) or BBV152 (n = 24). Blood samples were collected pre-vaccination, and at Day 7, 28, 180 and 360 post-booster for analysis of humoral and cellular immune responses. Primary end point was the SARS-CoV-2 anti-spike antibody titer at day 28. RESULTS: Recruitment began in January 2022 and was terminated early due to the BBV152 group meeting pre-specified criteria for futility. At Day 28 post-boost, mean SARS-CoV-2 spike antibody titers were lower with BBV152 (2004 IU/mL; 95 % confidence interval [CI], 1132-3548) vs mRNA (26,669 IU/mL; 95 % CI, 21,330-33,266; p < 0.0001), but comparable levels of spike-specific CD4 and cytotoxic T-cells were observed. Anti-spike antibody titers remained significantly different at Day 180: BBV152 4467 IU/mL (95 % CI, 1959-10,186) vs mRNA 20,749 IU/mL (95 % CI, 12,303-35,075; p = 0.0017). Levels of surrogate virus neutralizing antibodies against ancestral and Omicron subvariants BA.1 and BA.2 were significantly higher among mRNA recipients at Day 180, including after adjusting for intercurrent infection. By Day 360, anti-spike antibody titers and neutralizing antibody levels against Omicron subvariants became similar between vaccine groups. By the end of the study, 16 in each arm (mRNA 64 % and BBV152 69.6 %) had breakthrough infections and time to COVID-19 infection between vaccine groups were similar (p = 0.63). CONCLUSIONS: Wild-type SARS-CoV-2 anti-spike antibody titer and surrogate virus neutralizing test levels against wild-type SARS-CoV-2 and Omicron subvariants BA.1/BA.2/BA.5 were significantly higher at Day 28 and 180 in individuals who received booster vaccination with an mRNA vaccine compared with BBV152. CLINICAL TRIAL REGISTRATION NUMBER: NCT05142319.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Poh XY, Torres-Ruesta A, Yoong T, et al. Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial. Vaccine. 2024. PMID: 39241318. doi:10.1016/j.vaccine.2024.126275

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。